Colorectal cancer is the second leading cause of cancer death in the United States. More than 50,000 people are estimated to have died from colorectal cancer in the United States last year, according to...
Last Friday, March 8, 2019, marked another milestone in immuno-oncology: The U.S. Food and Drug Administration (FDA) announced the first approval of an immunotherapeutic for use in the treatment of breast cancer.
Rates of diabetes in the United States are increasing. According to statistics from the Centers for Disease Control and Prevention (CDC), an estimated 23 million Americans received a diagnosis of diabetes in 2015, in...
The FDA approved a new molecularly targeted therapeutic for patients ages 2 or older who have been diagnosed with a rare type of blood cancer called blastic plasmacytoid dendritic cell neoplasm.
The FDA recently approved a new anticancer therapeutic for treating patients with childhood acute lymphoblastic leukemia (ALL).
Immune-related adverse events (irAEs) is the collective term used to describe the side effects that arise in response to activation of the immune system by immunotherapies. As this class of cancer treatment yields undisputed...
The FDA expanded the use of pembrolizumab to treat certain patients with a rare, aggressive type of skin cancer called Merkel cell carcinoma.
Back for the new year, here are the editors’ selections for the January issues of the eight scientific journals published by the American Association for Cancer Research (AACR). Featured research highlights a wide variety...
The FDA approved a new molecularly targeted therapeutic called gilteritinib for treating certain patients with acute myeloid leukemia (AML).
The FDA approved the first molecularly targeted therapeutic for use based on a tumor biomarker rather than where the cancer originates.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More